Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market ...

Approved by the FDA in May 2024, Moderna’s mRNA shot, mRESVIA, only generated $10 million in sales during the third quarter, its RSV season debut. Besides the impact of a narrowed CDC policy ...

In that vein, let's learn about the three most important things you should know if you're going to consider investing in ...

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

With the triad of respiratory viruses present in our day-to-day, it is recommended that individuals receive both COVID-19, flu, and occasionally RSV and MPox vaccinations. However, there is a common ...

In addition to reporting 2024 revenue at the lower end of its previous guided range, Moderna issued a disappointing forward ...

Moderna and Novo Nordisk are once again in the bad books of the U.K.’s drug marketing watchdog. | Moderna and Novo Nordisk ...

"We remain focused on our three strategic priorities: driving sales growth, delivering up to 10 product approvals over the ...

Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The ...